This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Vimta Labs Q2 revenue up 10%, profit after tax up 3.5%
VIMTALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.4 pts less than Nifty Microcap 250 and 5.2 pts less than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Q2 revenue was INR 1,119.83 million, up 10.0% year on year, and profit after tax was INR 206.14 million, up 3.5%. For the half year ended 30 September 2026, revenue rose 10.9% to INR 2,210.57 million and profit rose 7.3% to INR 416.56 million. Operating cash flow was INR 459.37 million. The review was clean. No current exceptional charge applies; the year to March 2026 included a one-time INR 16.16 million labour-code gratuity cost. Prior figures were regrouped.
Steady growth and strong cash flow may support the stock, but slower profit growth and higher receivables need watching.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹112.0 Cr | ₹101.8 Cr | +10.0% |
| Operating profit | ₹24.62 Cr | ₹23.62 Cr | +4.3% |
| Profit after tax | ₹20.61 Cr | ₹19.92 Cr | +3.5% |
| EBITDA margin | 33.8% | 33.6% | +0.2 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.